Equities

Pulmonx Corp

Pulmonx Corp

Actions
  • Price (USD)8.38
  • Today's Change0.00 / 0.00%
  • Shares traded10.00
  • 1 Year change-31.59%
  • Beta0.7018
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Pulmonx Corporation is a commercial-stage medical technology company. The Company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its solutions, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), is designed to treat severe emphysema patients. The StratX Platform is a cloud-based quantitative CT analysis service that offers physicians with a report that is designed for its solution, which includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation and has been validated in multiple randomized controlled clinical trials.

  • Revenue in USD (TTM)72.99m
  • Net income in USD-58.73m
  • Incorporated2013
  • Employees279.00
  • Location
    Pulmonx Corp700 Chesapeake DrREDWOOD CITY 94063United StatesUSA
  • Phone+1 (650) 934-2600
  • Fax+1 (302) 655-5049
  • Websitehttps://pulmonx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Outset Medical Inc125.08m-168.77m206.37m480.00--2.21--1.65-3.38-3.382.501.800.35291.823.53260,577.10-47.61-41.40-54.98-47.2924.615.71-134.93-159.055.32-32.130.6786--13.00130.43-6.04--14.27--
Butterfly Network Inc68.08m-121.92m217.03m225.00--1.06--3.19-0.5893-0.58930.3290.96850.20450.69544.97302,577.80-36.61---42.07--26.50---179.08--3.34--0.00---10.21--20.76------
Delcath Systems Inc4.61m-49.79m218.12m76.00--13.66--47.35-2.65-2.650.23570.57470.13820.45454.5660,618.42-149.30-116.57-249.28-243.2170.5471.02-1,080.73-1,235.372.25-42.250.3348---24.05-9.53-30.60---5.26--
Neuropace Inc69.07m-31.51m218.64m171.00--15.22--3.17-1.18-1.182.590.49940.67351.626.63403,935.70-30.72---34.60--73.97---45.61--5.56-4.670.8019--43.72--30.00------
Edap Tms SA (ADR)65.46m-19.72m219.28m307.00--3.83--3.35-0.5326-0.53261.771.540.63772.393.53213,217.50-19.21-6.62-26.95-9.2240.9143.23-30.12-9.592.00--0.0757--9.649.05-622.06--32.75--
Utah Medical Products, Inc.49.04m16.38m236.65m169.0014.881.8810.954.834.514.5113.5035.600.37272.0913.24290,201.2012.4412.6913.0213.1959.0561.5733.3930.5117.89--0.0037.05-3.933.640.98341.659.711.86
Senseonics Holdings Inc23.30m-80.59m238.42m132.00--12.57--10.23-0.1354-0.13540.0390.10670.16352.516.51176,515.20-56.55-73.65-66.90-106.9712.93-40.41-345.89-649.863.70-11.130.4783--36.623.43-142.49---18.76--
AngioDynamics, Inc.324.01m-192.37m245.13m815.00--1.13--0.7566-4.78-4.788.105.410.74682.666.46397,555.80-44.34-9.12-54.02-10.1750.1754.23-59.37-19.481.62--0.00--7.135.30-97.54--3.55--
Sight Sciences Inc81.50m-54.75m262.71m214.00--2.40--3.22-1.12-1.121.672.200.46281.665.09380,822.40-31.09-38.78-33.65-42.2085.7380.74-67.18-105.1412.42-14.760.2358--13.6360.8435.59--6.77--
AxoGen Inc163.73m-21.28m267.03m426.00--2.87--1.63-0.4943-0.49433.802.130.87091.497.04384,333.30-11.32-13.92-12.82-15.8478.3479.74-13.00-20.282.23-8.760.3346--14.7413.6324.98--17.70--
Tactile Systems Technology Inc276.67m28.19m303.68m992.0010.801.578.741.101.181.1811.708.141.016.776.05278,896.2010.300.901512.181.0949.9849.1010.190.83093.63--0.1280.0011.2013.81259.6033.91-23.62--
Treace Medical Concepts Inc196.03m-54.75m312.52m516.00--2.47--1.59-0.8885-0.88853.182.040.7971.287.07379,905.00-22.26---25.98--80.99---27.93--3.22--0.2958--31.92---15.68------
Pulmonx Corp72.99m-58.73m325.28m279.00--2.94--4.46-1.54-1.541.912.850.3991.147.81261,627.20-32.11-26.27-35.87-28.9774.3171.95-80.46-93.766.14--0.252--27.9827.98-3.26--20.62--
Zynex Inc188.68m8.17m326.97m1.10k45.5110.0725.851.730.22610.22615.391.021.592.526.56171,530.006.8914.588.4117.5280.2279.624.3310.442.877.240.6381--16.5442.01-42.910.37412.19--
Nevro Corp430.75m-82.59m344.88m1.22k--1.24--0.8007-2.28-2.2811.907.590.7361.146.04354,523.50-14.11-13.64-16.06-16.6868.9468.54-19.17-20.675.57--0.4354--4.631.88-3,172.74--0.9012--
Jin Medical International Ltd19.98m3.25m439.90m269.00125.9018.50122.9322.020.02230.02230.13530.15190.75571.855.0074,260.5212.28--16.62--33.02--16.25--3.02--0.0582---7.58--2.84------
Data as of May 23 2024. Currency figures normalised to Pulmonx Corp's reporting currency: US Dollar USD

Institutional shareholders

60.12%Per cent of shares held by top holders
HolderShares% Held
PRIMECAP Management Co.as of 31 Mar 20245.74m14.89%
Fidelity Management & Research Co. LLCas of 31 Mar 20244.25m11.02%
Point72 Asset Management LPas of 31 Mar 20242.72m7.05%
Morgan Stanley & Co. LLCas of 31 Mar 20242.45m6.36%
BlackRock Fund Advisorsas of 31 Mar 20242.41m6.25%
The Vanguard Group, Inc.as of 31 Mar 20241.98m5.14%
BNP Paribas Asset Management USA, Inc.as of 31 Mar 2024989.42k2.57%
SSgA Funds Management, Inc.as of 31 Mar 2024974.68k2.53%
Geode Capital Management LLCas of 31 Mar 2024834.52k2.17%
Victory Capital Management, Inc. (Investment Management)as of 31 Mar 2024826.30k2.14%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.